Funded Startups in Belmont
Among the 10 most recent rounds shown, the largest disclosed amount is Cellink’s $250M (Series D) on 2022-02-16, which dwarfs the next-largest disclosed am…
Among the 10 most recent rounds shown, the largest disclosed amount is Cellink’s $250M (Series D) on 2022-02-16, which dwarfs the next-largest disclosed amounts: Solve Therapeutics at $120M (2025-11-21) and ZaiNar at $100M (2026-02-19). The majority of disclosed figures cluster closer to the $13M–$50M range (e.g., 4D Path $13M on 2023-05-03; Guidde $50M on 2026-02-25; Avegant $15M on 2025-05-21).
Geographically, the “Belmont” entries split between Belmont, California (Mendral; Guidde; ZaiNar; Solve Therapeutics; Avegant; Themis AI) and Belmont, Massachusetts (Circular Labs; 4D Path; Cellink; BioROSA Technologies). Temporally, the list spans 2026-04-14 (Mendral) back to 2021-11-10 (BioROSA Technologies), with two releases in early 2026 (2026-02-19 and 2026-02-25) followed by a 2025 concentration (Avegant 2025-05-21 and Solve Therapeutics 2025-11-21). Stage/label coverage is mixed: 5 of 10 rows are “undisclosed” or “Series Unknown,” including Mendral (undisclosed, 2026-04-14), Themis AI (undisclosed, 2023-05-09), and BioROSA Technologies (Venture - Series Unknown, 2021-11-10).
Most recent rounds
10 shownRelated listings
Frequently asked
Which disclosed round is an outlier in Belmont, and how does it compare to the next-largest disclosed amounts?
Cellink’s $250M (Series D) on 2022-02-16 is the standout outlier; the next-largest disclosed amounts in the table are $120M for Solve Therapeutics (2025-11-21) and $100M for ZaiNar (2026-02-19).
Do the rounds cluster in time, particularly around early 2026 or late 2025?
Early 2026 has two entries close together: ZaiNar at $100M on 2026-02-19 and Guidde at $50M on 2026-02-25. Late 2025 also shows up as a pair of disclosed rounds: Avegant at $15M on 2025-05-21 and Solve Therapeutics at $120M on 2025-11-21.
Are there city-level patterns across “Belmont,” especially CA vs MA?
The list is split between Belmont, California (Guidde $50M on 2026-02-25; ZaiNar $100M on 2026-02-19; Solve Therapeutics $120M on 2025-11-21; Avegant $15M on 2025-05-21; Themis AI undisclosed on 2023-05-09; Mendral undisclosed on 2026-04-14) and Belmont, Massachusetts (Cellink $250M on 2022-02-16; 4D Path $13M on 2023-05-03; Circular Labs undisclosed on 2024-08-23; BioROSA Technologies undisclosed on 2021-11-10).
What stage or label mix dominates the disclosed vs undisclosed entries?
Exactly half of the 10 rows lack a disclosed amount or a specific series label: Mendral (undisclosed, 2026-04-14), Circular Labs (undisclosed, 2024-08-23), Themis AI (undisclosed, 2023-05-09), BioROSA Technologies (undisclosed, 2021-11-10), plus Solve Therapeutics is labeled “Venture - Series Unknown” despite a $120M disclosed figure on 2025-11-21.
Which sectors show up most often in this Belmont set?
Artificial Intelligence appears most frequently with 3 entries: Guidde (2026-02-25, $50M, Series B), ZaiNar (2026-02-19, $100M, Series B), and Themis AI (2023-05-09, undisclosed). Biotechnology/Pharmaceuticals also clusters with 3 entries across biotech-focused rounds: Solve Therapeutics (2025-11-21, $120M), 4D Path (2023-05-03, $13M), and BioROSA Technologies (2021-11-10, undisclosed).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.